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Abstract
Background: Opioid dependence has devastating and increasingly widespread consequences and costs, and the
most common outcome of treatment is early relapse. People who inject opioids are also at disproportionate risk for
contracting the human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This study tests an approach that
has been shown to improve recovery rates: medication along with other supportive services (medication-assisted
treatment, or MAT) against MAT combined with a smartphone innovation called A-CHESS (MAT + A-CHESS).
Methods/design: This unblinded study will randomly assign 440 patients to receive MAT + A-CHESS or MAT alone.
Eligible patients will meet criteria for having an opioid use disorder of at least moderate severity and will be taking
methadone, injectable naltrexone, or buprenorphine. Patients with A-CHESS will have smartphones for 16 months;
all patients will be followed for 24 months. The primary outcome is the difference between patients in the two
arms in percentage of days using illicit opioids during the 24-month intervention. Secondary outcomes are
differences between patients receiving MAT + A-CHESS versus MAT in other substance use, quality of life, retention
in treatment, health service use, and, related to HIV and HCV, screening and testing rates, medication adherence,
risk behaviors, and links to care. We will also examine mediators and moderators of the effects of MAT + A-CHESS.
We will measure variables at baseline and months 4, 8, 12, 16, 20, and 24. At each point, patients will respond to a
20- to 30-min phone survey; urine screens will be collected at baseline and up to twice a month thereafter. We will
use mixed-effects to evaluate the primary and secondary outcomes, with baseline scores functioning as covariates,
treatment condition as a between-subject factor, and the outcomes reflecting scores for a given assessment at the
six time points. Separate analyses will be conducted for each outcome.
Discussion: A-CHESS has been shown to improve recovery for people with alcohol dependence. It offers an
adaptive and extensive menu of services and can attend to patients nearly as constantly as addiction does. This
suggests the possibility of increasing both the effectiveness of, and access to, treatment for opioid dependence.
Trial registration: ClinicalTrials.gov, NCT02712034. Registered on 14 March 2016.
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Background
Opioid dependence has devastating consequences for
patients, family members, and communities. In 2012, an
estimated 2.1 million Americans had opioid use disor-
ders (OUDs) related to prescription opioids, and 467,000
had OUDs related to heroin [1]. The total volume of
opioids prescribed in the health care system has risen
steeply in recent years. In 1991, about 76 million pre-
scriptions were written for opioids; in 2013, about 207
million prescriptions were written [2]. A growing pro-
portion of people with OUDs started their use of opioids
by taking prescription opioids. Emergency department
visits related to the nonmedical use of opioids rose from
144,600 in 2004 to 305,900 in 2007 [3] and unintentional
overdose deaths from opioids have more than quadru-
pled since 1999, reaching their highest level ever in 2014
[2, 4]. OUDs also have been a primary driver of the in-
creased spread of human immunodeficiency virus (HIV)
and hepatitis C virus (HCV) in many rural and suburban
communities in the US [5, 6].
Existing treatments for OUDs often fail. Following
detoxification from opioid dependence, early relapse is the
most common outcome [7]. After inpatient treatment, the
vast majority of patients relapse within a year, often within
the first few months [8]. Medication-assisted treatment
(MAT) arose when methadone became available in the
1960s. Along with other supportive services, such as peer
support, MAT has been shown to increase rates of recov-
ery from OUD [9]. Yet those who receive MAT still do
not generally maintain long-term abstinence [8, 10].
Access to treatment is an enormous challenge, with
only 10.7% of OUD patients who needed treatment in
2012 receiving it [11]. Effective treatment is complex
and demanding because OUDs are chronic diseases that
require ongoing medication, behavioral counseling, and
overdose protection, as well as screening and treatment
for infectious disease and comorbid psychiatric disease
[2]. Effective treatment is also complex because affected
populations differ in the etiology and course of their ad-
diction, motivation for treatment, and reasons for
relapse, including notable differences between men and
women [12]. For example, women tend to progress more
quickly from the start of substance use to the start of de-
pendence, have a higher rate of cooccurring mood and
anxiety disorders, and have better outcomes on bupre-
norphine than on methadone [12]. Finally, retention in
treatment, which is known to reduce drug use [13],
remains a challenge in treating OUDs [14–19]—so much
so that treatment retention is often itself regarded as a
desired outcome [20].
Testing and links to care for HIV and HCV are essential
for people who inject opioids. Those who inject drugs are
at greater risk of contracting HIV and are less successfully
linked to [21–23] and retained in [24–26] clinical care.
Antiretroviral therapy is recommended for all patients liv-
ing with HIV, but treatment is under-used [27] and often
suboptimally effective [23, 28] among people who inject
drugs. HCV occurs primarily in people who inject drugs,
with 90% of older injection-drug users infected [29–31].
HCV is the most common blood-borne infection in the
US [32] and the most common cause of end-stage liver
disease and the need for liver transplants.
The randomized clinical trial described here assesses
the extent to which the considerable challenges of effect-
ively treating OUDs can be addressed by an mHealth
intervention. Specifically, we pair MAT with a
smartphone-based innovation called Addiction CHESS
(A-CHESS). A large (n = 349) randomized controlled
trial (RCT) previously found that A-CHESS decreased
risky drinking days and enhanced long-term abstinence
among alcohol-dependent people leaving residential
treatment, one third of whom reported illicit opioid use
[33]. Related field tests in the Veterans Administration
and drug courts and among pregnant women in Appala-
chia [34] also found a positive impact on alcohol and
opioid abuse of providing smartphones with A-CHESS.
In this trial, we assess the potential of A-CHESS to
improve long-term outcomes of MAT among OUD
patients. Furthermore, the study seeks to understand—-
through analyses of mediators and moderators and
exploratory analyses—the ways in which A-CHESS
works and does not work, for whom, and under what
circumstances. Our research team has also developed
and pilot-tested systems for improving engagement in
care for patients with HIV and improving testing and
links to care for patients with HCV. For the present
study, these innovations related to HIV and HCV have
been incorporated into A-CHESS, allowing us to evalu-
ate whether A-CHESS can also improve screening and
treatment outcomes for these conditions.
Methods/design
Study design, hypotheses, and outcomes
The study, a RCT, will assign 440 opioid users from
three addiction treatment centers to receive either MAT
+A-CHESS or MAT alone. Patients will be followed for
24 months. The primary hypothesis is that participants
assigned to MAT + A-CHESS will have, compared with a
control group, a lower percentage of days using illicit
opioids. Secondary hypotheses are that those assigned to
MAT +A-CHESS will have, compared to the control
group, less use of other nonprescribed substances,
higher quality of life, greater retention in treatment, and
lower health service use. Secondary hypotheses related
to HIV/HCV are that those assigned to MAT +A-
CHESS will have higher screening and testing rates,
greater medication adherence, fewer risk behaviors, and
better linkage to care (i.e., referrals that result in in-
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person visits with providers). We also hypothesize that
autonomy (or intrinsic motivation), competence, and
relatedness [35] will mediate the effect of MAT +
A-CHESS, along with negative affect and self-stigma.
We will also determine the person-level factors that
moderate the impact of MAT +A-CHESS versus MAT
alone (e.g., gender, SUD severity, pain severity, severity
of withdrawal symptoms, and loneliness). For patients
receiving MAT +A-CHESS, we will examine whether
patterns of using A-CHESS and communication style
within peer discussion forums are predictors of study
outcomes [36]. Figure 1 shows the logic and outcomes
for the project. We will use quantitative and qualitative
analyses to examine long-term impact, with survey data
collected every 4 months during the 24-month period.
Interventions
Control condition: MAT
Patients in the control condition will receive treatment as
usual including MAT. Treatment could consist of a recov-
ery plan, medication, and regularly scheduled behavioral
interventions such as monthly group counseling sessions,
sessions with a substance abuse counselor, and Narcotics
Anonymous/Alcoholics Anonymous (NA/AA) meetings.
Medication may include methadone, injectable naltrexone,
or buprenorphine. The sequence and duration of medica-
tion and behavioral interventions will vary by patient and
site. Discussions with sites revealed that we should not try
to control variations because they are tailored to individ-
ual patients. We will document which medications are
used and will include as covariates when and how medica-
tions change between the 4-month surveys.
Experimental condition: MAT + A-CHESS
Patients in the experimental condition will receive a
smartphone with A-CHESS for 16 months along with
MAT as described above. A-CHESS is designed to im-
prove recovery from addiction. A-CHESS is based on self-
determination theory (SDT), which holds that meeting
three needs—for autonomy, competence, and
relatedness—improves a person’s adaptive functioning [35,
37]. Figure 2 shows how A-CHESS services relate to the
constructs of SDT and to the determinants and anteced-
ents of relapse identified by Marlatt [16, 38, 39]. A-CHESS
services provide antecedent-appropriate intervention(s)
that boost autonomy (intrinsic motivation) by selecting
from multiple services those most likely to be most per-
sonally meaningful to the patient; offer information, moni-
toring, and tools to increase competence; and/or increase
relatedness. For example, the lower part of Fig. 2 shows
antecedents of relapse, one of which is lifestyle imbalance
(lower left of figure) and Marlatt’s suggestion that develop-
ing substitute indulgences helps (second level-left). The
left upper section shows how A-CHESS helps. Another
example: A-CHESS monitoring tools include a weekly
check-in and GPS-based tracking to identify when lifestyle
imbalance may place a patient at risk of using drugs or en-
gaging in unsafe sex. As one healthy alternative, the
A-CHESS healthy events calendar may suggest one of the
patient’s healthy pleasures, such as going for a walk, and
offer a map. We anticipate that this just-in-time approach
may be important to help maintain abstinence. Figure 3
shows the A-CHESS user interface. Key A-CHESS ser-
vices are described below.
Help. When a patient presses Help, the system shows
a list of the patient’s preapproved supporters and their
phone numbers so the patient can easily call for help.
The patient can also be linked to positive and potentially
distracting activities such as selected games [40] and
audio/video-based relaxation recordings [41].
Cognitive behavioral therapy (CBT) boosters offer brief,
easy-to-remember reviews of CBT skills that patients
learned during treatment to prepare them for future
challenges—e.g., how to handle urges and anticipating,
avoiding, and mitigating the effects of high-risk people,
places, and things related to past drug use.
Fig. 1 Logic and outcomes of the study
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Monitoring functionality includes the location tracker
(described below), self-assessment tools, and a record of
A-CHESS use. One self-assessment tool is the Brief
Addiction Monitor (BAM) [42], which we implement as
a weekly survey. After completing the BAM, participants
receive tailored feedback that acknowledges their use of
protective behaviors over the past week and provides
recommendations for addressing risky behaviors, includ-
ing links to appropriate A-CHESS content. Participants
reporting opioid or other drug use will be encouraged to
seek appropriate help.
The location tracker uses GPS to monitor patient
movement. If a patient approaches a location that they
previously defined as high risk, A-CHESS will initiate a
patient-defined recovery process. This might start with a
beep, then a vibration, and then a list of preapproved
contacts and options for distraction or mindfulness. The
GPS service is also often used to find a 12-step meeting.
Patients may turn off the location tracker if they per-
ceive certain services to be too burdensome or invasive.
Triage and feedback functionality is designed to derail
the relapse process, giving the patient just-in-time,
tailored coping support. A-CHESS will be customized at
the start by each patient to set options that will be trig-
gered in a moment of need. For example, if a patient
reports a craving triggered by environmental cues, such
as seeing someone else use, A-CHESS might remind the
patient of relaxation exercises, connect them to online
peer support and the healthy events calendar, and/or
notify a counselor, who may initiate contact via text or
private message. Participants whose patterns of using
A-CHESS demonstrate they are likely to stop using the
system will receive automated messages and tailored
messages from coaches to encourage them to reengage.
The counselor dashboard [43], developed by addiction
physicians and psychologists, harvests clinically relevant
data from A-CHESS and presents it to counselors to
help them quickly: (1) identify patients who may be at
high risk for relapse and/or benefit from clinical inter-
vention, (2) see a detailed analysis of a patient’s recent
Fig. 2 Overview of patient-facing A-CHESS services
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history, e.g., trends in individual BAM items, A-CHESS
use, and relapse data, and (3) intervene with patients
(e.g., through texting in A-CHESS). When a counselor
logs into the counselor dashboard, he sees ‘red pins’
generated when A-CHESS (using counselor-determined
priorities) detects that a patient may be at high risk. The
counselor can adjust the cutoffs for red pins so the ones
he sees are most useful.
HIV/HCV services. A-CHESS will integrate compo-
nents of our team’s existing computerized risk reduction
systems that collect data on patients’ HIV/HCV risk
behaviors and deliver behavior change interventions
tailored to the patient’s self-reported readiness for
change. At enrollment, participants in both study condi-
tions will be asked if they have been screened for HIV
and HCV. Patients who test negative or decline testing
at baseline will be sent reminders from A-CHESS about
future testing at a frequency based on reported risk be-
haviors. Patients found to be HIV or HCV-positive will
be provided with targeted multimedia health education
content, access to online resources, and location-specific
links to clinical care and case management.
Coach-monitored discussion groups [44] foster the
exchange of emotional, informational, and instrumental
support among patients. Discussions are monitored daily
by an A-CHESS coach to encourage appropriate use.
Coaches are not counselors, but are members of the
research team trained on A-CHESS, risk identification,
referral, and technology-based patient engagement. They
are skilled in constructive interaction and persistence
and are willing to work unusual hours. The coaches en-
courage individuals to follow up with their health care
providers/prescribers regarding medication-assisted
treatment questions. We found that a coach increases
and sustains use of A-CHESS [45]. Every week, a coach
reviews use data. Based on what the coach sees, they
write messages to the participants. For example, (1) to a
patient active on A-CHESS, “Hi kfields05, Just wanted to
say hello and see how things are going. Looks like you
are doing a great job of recovery and tracking, which is
wonderful. Let me know if there is anything I can help
with. Take care and keep it up! Coach Lola.” and (2) to a
patient who is not logging in: “Hi Teresa H, Just check-
ing in to see how you are coming with your recovery
goals. You have not logged in for a while so I figured I
would say hi. Take care and let me know what I can do
to help! Coach Lola.”
Possible counselor alerts. A-CHESS sends an email
notification to an A-CHESS coach if a patient reports
substance use or is over a preset risk threshold on self-
monitoring items. The coach may alert a counselor or
encourage the patient to seek further support within
A-CHESS (e.g., by using discussion groups, games, and
relaxation exercises; revisiting their personal recovery
motivation; or listening to personal stories from others
in recovery) or recommend that the patient seek other
professional help.
Ethics
The study received approval from the Health Sciences
Institutional Review Board at the University of
Wisconsin-Madison (#2015-1418) and the Western
Institutional Review Board (#1163410) in Puyallup,
Washington and is registered at ClinicalTrials.gov
(NCT02712034). The study complies with the relevant
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) Statement and World Health
Organization Checklist (see the SPIRIT Checklist and
figures in Additional files 1 and 2). The study is funded
by the United States Department of Health and Human
Services National Institute on Drug Abuse.
Patient eligibility
Patients will be recruited from outpatient detoxification
and treatment programs at three sites, two in Massa-
chusetts and one in Wisconsin. Patients are eligible for
Fig. 3 A-CHESS user interface
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the study if they (1) are currently on MAT (methadone,
injectable naltrexone, or buprenorphine) for their sub-
stance use disorder (SUD), (2) are aged 18 years or
older, (3) meet criteria for having an OUD of at least
moderate severity (4 or 5 Diagnostic and Statistical
Manual of Mental Disorders, fifth edition (DSM-V) cri-
teria), (4) have no acute medical problem requiring im-
mediate inpatient treatment, (5) have no history of
psychotic disorders, though patients with other comor-
bid psychopathology (mood disorders, anxiety, other
substance use disorders) will be eligible, (6) are willing
to participate in a randomized clinical trial, (7) provide
the name, verified phone number, and address of at
least two contacts willing to help locate the patient, if
necessary, during follow-up, (8) are able to read and
write in English, (9) are not pregnant, (10) are willing
to share health-related data with primary care clini-
cians, and (11) are, at study intake, abstinent from opi-
oids for at least 1 week and no longer than 2 months,
except for medications used to treat the disorder.
Recruitment
Potential subjects will be identified by a staff person at
each of the three sites and asked if they are interested in
learning about a study for which they may be eligible. If
they answer yes, the University of Wisconsin (UW) or
site coordinator will provide a detailed overview of the
study, including patient responsibilities and how patient
confidentiality will be protected. Interested patients will
then provide informed consent, complete a baseline sur-
vey, be randomized to receive MAT + A-CHESS or
MAT, and, if applicable, be trained on A-CHESS.
Figure 4 shows the flow of participants through the trial.
Randomization
The project director will use a computer-generated allo-
cation sequence to randomize participants in a 1:1 ratio
to MAT +A-CHESS or MAT alone, stratifying on gender
and site and balancing on age, level of care (intensive
outpatient treatment, day treatment, or weekly or
monthly counseling), and whether patients had prior
SUD treatment. The project director will inform the site
coordinator of the group assignment by email; in the
email, the participant will be identified only by study ID
(the code used to make the identity of participants
unknown). The site coordinator will initiate patients into
the study condition and, if the patient is assigned to
MAT +A-CHESS, provide training.
Smartphone distribution
Patients randomized to MAT + A-CHESS who do not
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Fig. 4 Participant flow
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loaded with A-CHESS, along with a data plan that in-
cludes unlimited data, text, and voice for 16 months.
Patients who already have an Android smartphone will
have A-CHESS installed on their phone. We will provide
up to one replacement phone to patients who report
their phone lost, stolen, or broken. If patients lose the
second phone, we will offer to load A-CHESS onto an
appropriate replacement smartphone (e.g., Samsung S5)
that they obtain. We have included in the budget a 20%
allowance for replacement phones, which has proven
sufficient in prior CHESS research, including trials with
populations of addicted patients [33, 46].
Training to use A-CHESS
The UW or site coordinator will train patients to use
the A-CHESS app and customize it − e.g., by sources of
support (such as family), contacts who detract from
recovery (such as friends who use illegal drugs) and sup-
port recovery, and so on. A-CHESS will be updated
monthly with activities for the healthy event calendar;
changes, if any, to therapeutic goals and the recovery
plan (e.g., self-help groups, medication) and in home,
work, or educational responsibilities; and high-risk
locations to avoid. Patients must demonstrate that they
can use A-CHESS (e.g., make one post to the discussion
group) before they leave the training session with the
phone.
Quantitative data collection
All subjects will complete follow-up surveys over the
phone with the UW study coordinator at months 4, 8, 12,
16, 20, and 24. Data collected will relate to the variables
shown in Fig. 1. Each phone survey is expected to take 20
to 30 min. Surveys will be identified by study ID, not par-
ticipant name. The form linking study IDs and names will
be kept in REDCap [47]. In addition, urine screens, which
are done routinely as part of MAT, will be conducted at
each study site and recorded for all subjects at baseline
and up to twice a month thereafter. Results will be used to
validate self-reported information. Inconsistent results be-
tween urine drug tests and self-report results will not
affect patients’ ability to continue in the study.
Qualitative data collection
We will administer in-depth interviews with patients to
shed light on their perspectives as well as on what
promotes and hinders implementing and sustaining
MAT +A-CHESS. We will explore patient perceptions
of the effects of integrating MAT +A-CHESS, the most
and least useful services in A-CHESS, gender-specific
effects, and how patients feel about various A-CHESS
services over time. A second set of interviews will exam-
ine provider perceptions of benefits of and barriers to
integrating and sustaining MAT +A-CHESS over time.
A third set of interviews will examine fine-tuning MAT
+A-CHESS; communication between the research team,
patients, and providers; and concerns from providers
and patients. These data will help to refine methods for
developing mHealth systems generally.
UW research staff will also conduct a longitudinal case
study of five female and five male patients to explicate
MAT +A-CHESS effects, considering patients’ medical
and addiction treatment history, family history, personal
and gender-specific preferences, and environmental
factors. Case studies, though underused in health care [48],
are a good way to understand how innovations work in real
life [49]. They provide insight into patterns that might be
overlooked in RCTs because they reveal the complexities of
systems in which innovations are introduced. By following
these ten individuals over time, we will explore how women
and men integrate new technologies into their lives,
circumstances that favor or complicate the process, and
barriers to sustainability. Data collection from interviews
and focus groups will ensure the comprehensiveness of
findings and strengthen validity [50].
Measures
All scales have good psychometric properties with simi-
lar populations. Listed below are the factors to be
measured and instruments to be used, along with refer-
ences to validation studies for the instruments.
Intake and baseline. Treatment center staff will docu-
ment patient eligibility. Then patients will complete the
baseline survey. They will report 12 demographic items
(gender, age, race, education, etc.) and five items related
to their opiate use history (age of first use, age of regular
use, whether opioid use began with a physician-
prescribed opioid, number of past quit attempts, and
date of last use). Patients will also respond to items re-
lated to chronic pain diagnosis and treatment, current
and past comorbid psychiatric diagnoses and treatment,
pain severity (using the Numeric Rating Scale (NRS-11))
[51], and HIV/HCV status.
Dependent variable. Self-reported illicit opioid use
days will be analyzed in 30-day periods. At baseline, a
Timeline Followback (TLFB) [52] for the 30 days before
admission will be obtained (with opioid use separated
from other drug use) and a urine drug screen collected
(CTN-approved drug use outcome measures). For
follow-up assessments, the TLFB for the previous
120 days will be obtained. The TLFB has been success-
fully used to obtain drug use data for extended periods
of time and with polydrug-using patients [53].
At months 4, 8, 12, 16, 20, and 24. During phone sur-
veys after baseline data collection, patients will complete
a 120-day TLFB [54] to document their illicit opioid and
other nonprescribed drug and alcohol use as well as
health service use during the past 4 months. Health
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service use will be collected for the categories listed under
“Health service use and cost” below. Patients will also
complete measures of: relapse risk (Brief Addiction Moni-
tor [55], nine items); pain severity (NRS scale [56], one
item); HIV/HCV screening and link-to-care status (testing
status and if tested, result, and if positive, whether the pa-
tient saw a medical provider); risk behaviors (HRBS [57],
five items); status of current housing (two items) and em-
ployment (three items on type of employment, hours
worked); quality of life (The Satisfaction with Life Scale
[58], eight items); rating scale for withdrawal (three items);
self-reported medication adherence (Morisky Medication
Adherence Scale: MMAS-4 [59], four items); and loneli-
ness (three items). We will collect number of phones lost,
stolen, or broken (research records). For retention in
treatment, we will take the proportion of appointments
attended from clinic records. We will also determine if
participants are engaging in other forms of treatment out-
side of the treatment facility, such as seeing a therapist,
working with a sponsor, or attending NA/AA meetings.
Mediators. Self-determination theory (SDT) constructs
will be assessed as follows: autonomy, Treatment Self--
Regulation Questionnaire [60] (six items); competence,
revised Drug-Taking Confidence Questionnaire [61]
(eight items); and relatedness, our own bonding scale
(five items). Negative affect will be assessed by Positive
and Negative Affect: PANAS [62, 63] (20 items), and
self-stigma by the self-devaluation subscale of the self-
stigma in substance abuse scale [64] (seven items).
Moderators: we will focus our evaluation on gender
but also collect data on other potential moderators
(SUD severity as determined by the treatment site at
intake using DSM-V criteria, pain as determined by the
NRS-11, withdrawal, and loneliness).
A-CHESS use. A-CHESS use will be collected in time-
stamped log files and includes when a patient accessed
A-CHESS, service(s) selected, duration of service use,
pages viewed, messages posted versus received, and
communication style and content of messages. Content
will be subject to computer-automated content analysis
to identify communication styles that may predict study
outcomes. Cumulative use (number of pages viewed and
days used) significantly predicted risky drinking days in
the randomized trial of A-CHESS with alcohol-
dependent patients [33]. We will also collect data on
sources of other SUD-related information and support.
Health service use and cost. Our cost analysis is moti-
vated by the potential that A-CHESS has shown to
reduce the use of costly health services associated with
relapse. (In a field test with US military veterans,
A-CHESS users had substantially decreased rehospitali-
zations related to relapse.) Our approach to measuring
and analyzing health use data is adapted from McCollis-
ter and French’s 2003 analysis of the economic benefit of
addiction interventions [65]. We will use the following
categories of health service use: emergency room visits,
hospital detox (day), and short-term residential treat-
ment (day). We will also track costs for all other hospital
visits and stays (in addition to emergency room visits
and hospital detox); urgent care visits for any reason (to
which we will apply cost estimates derived from a
national survey of urgent care clinics [66]; individual
psychotherapy or psychiatric care; and self-reported out-
patient addiction treatment services after relapse (using
the categories of outpatient addiction care outlined by
McCollister and French [64], to which we will apply cost
estimates provided in the 2008 national survey of 110
substance abuse treatment programs by French et al.,
adjusted for inflation [67]). We will also collect self-
reported use of other health services (e.g., dental care,
primary care, chiropractor), following the approach by
Bell et al., to assess the cost-effectiveness of supervised
versus unsupervised buprenorphine-naloxone adminis-
tration [68]. We will derive cost estimates for various
types of health care use (e.g., emergency room visits,
hospitalizations, primary care visits, etc.) using data from
the American Hospital Association and the American
Medical Association.
Timeline
Recruitment began in April 2016 and will end in
February 2018. The intervention period will end in
February 2020. Figure 5 shows the study timeline.
Data analysis
Power and sample size justification
Primary analysis. Our study will be powered to detect a
difference between MAT +A-CHESS and MAT in
Year: 2016 2017 2018 2019 2020












Fig. 5 Study timeline
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percentage of days using illicit opioids across the 24-
month intervention period. Based on data from the two
sites from which most study participants will be re-
cruited, we assume 35% attrition over the course of the
study, providing an N of 286. Using the power program
by Hedeker et al. [69] and assuming up to cubic trends
in the data, given expected attrition, recruitment of 440
patients will provide 80% power to uncover a standard-
ized difference of .35 across the 24 months. From prior
data [70, 71], this would be a difference of approximately
three opioid use days/month depending on the observed
standard deviation.
Secondary analyses. Power for examining intervention
effects for the secondary outcomes would be similar as
for the percentage of opioid use days, though the differ-
ence implied by the standardized difference of .35 will
depend on the actual standard deviation of each meas-
ure. For secondary outcomes related to HIV and HCV,
the sample size also provides 80% power to find a two-
tailed difference in proportion screened for HIV/HCV of
16% [72] (conservatively assuming that screening for
one group nears 50%, the point requiring the largest dif-
ference to achieve a specified power).
Mediation and moderation analyses. Power for detect-
ing specific parameter changes in the structural model
will be estimated using a procedure proposed by Satorra
and Saris [73] that approximates the noncentral chi-s-
quare distribution. A total N of approximately 220 pa-
tients would provide adequate power (>.80) to detect a
group difference in a parameter by 0.4 standard devia-
tions (a moderate effect). Since our primary analysis pro-
jects a final N of 286, we are confident our secondary
process analysis will have adequate power.
Missing data. In previous addiction work, we completed
85% of surveys at 4, 8, and 12 months. We anticipate
greater reductions at months 16, 20, and 24, reaching
about 65% by month 24. In previous studies, we have kept
missing data on core items in a survey to about 2% and
expect a comparable rate in this study. In addiction treat-
ment, data are not likely to be missing at random (i.e., the
probability that data are missing is related to what the data
would have been had the data been observed). For ex-
ample, some patients may not want to disclose opioid use
in surveys. Because this may lead to biased parameter esti-
mates for our models, we will identify missing data pat-
terns and use pattern-mixture modeling to test the
sensitivity of our longitudinal intervention analysis to
missing data assumptions [74–77] and conduct other sen-
sitivity analyses after imputing missing data with a range
of clinically plausible values based on explicit assumptions
for the missing data (e.g., best-case, worst-case; with and
without multiple imputation) [78–80].
Intention-to-treat and subject noncompliance. Stand-
ard intention-to-treat (ITT) estimates the average
treatment effect by comparing outcomes based on as-
signment to treatment, but ignoring use of the treat-
ment. Because ITT estimates do not represent treatment
efficacy under noncompliance (e.g., a patient is random-
ized to A-CHESS but does not use the system), we will
address noncompliance by also estimating treatment
effects only for compliers using as-treated, per-protocol
[81], and CACE (Complier Average Causal Effect) [82].
Dropout rates. In our A-CHESS RCT with alcohol-
dependent patients [33], 88 patients were using opioids
as well as alcohol; 261 were not using opioids. We com-
pared the post-test survey response rate of opioid-using
patients to the response rate of patients who did not use
opioids. The non-opioid-using patients’ response rates
were 94.3% at 4 months; 90.6% at 8 months, and 86.7%
at 12 months. The opioid-using patients’ response rates
were 91.2%, 86%, and 79.1%. Response rates declined in
a relatively linear fashion in both groups, with reduc-
tions of about 5 percentage points in each period. We
assumed a 65% response rate at 24 months by continu-
ing the drop off rate for each of the three periods from
79% to 74% to 69% to 64%. Hence, we believe it is likely
that by the end of the study we will still be able to reach
65% of patients originally enrolled.
Mediation analysis. Mediator variables will all be col-
lected in the first two visits (at the 4- and 8-month
visits) while the outcome (illicit drug use days) will be
collected at months 12, 16, 20, and 24. Because
mediator-outcome relations might reflect the effects of
drug use while the mediator is being assessed (e.g., drug
use might suppress ratings of competence), drug use
that occurs during the mediator assessment period will
be covaried out of models to examine and control its in-
fluence. Moreover, to assess the nonorthogonality of the
mediators (which seems likely with the self-
determination variables), we will use multiple mediator
analyses based on a Bayesian approach illustrated in
Yuan and MacKinnon [83]. This Bayesian estimation of
the meditational models can be implemented through
Markov Chain Monte Carlo (MCMC) techniques. Unlike
more traditional estimation methods, such as maximum
likelihood or least squares methods, for example,
MCMC methods rely on sampling techniques to esti-
mate model parameters and resulting mediation effects
(i.e., iterative sampling from the parameter distributions
is used to estimate confidence intervals to identify sig-
nificant effects). An appealing feature of the method is
its relative ease of implementation, particularly for com-
plex statistical models. Similar to Yuan and MacKinnon,
we will implement MCMC using WinBUGS 1.4 [84].
The multiple mediator models will be conducted with
only those mediators shown to be significant in univari-
ate models. See Bolt et al. [85] for our previous applica-
tion of this analytic approach.
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Qualitative analysis. Content analysis [86] of interview
transcripts will describe the role that MAT +A-CHESS
plays in sustaining opioid recovery and reducing HIV/
HCV risk; identify potential improvements in MAT and
A-CHESS; and supplement the quantitative analysis.
UW research staff will: (1) construct a coding scheme
[87] by combining categories flowing from the research
questions, categories used in previous studies, and a pre-
liminary examination of the data. Ideas will be our unit
of analysis (rather than words or paragraphs) to capture
references to a concept as well as direct statements
about it, (2) test the coding scheme on a sample of data.
Three coders will independently code the data in NVivo.
We will calculate intercoder reliability and develop a set
of coding instructions to insure reliability of at least .80,
(3) code the full dataset and create a conceptual model
to help explain the mechanisms by which, and condi-
tions under which, the interventions affect opioid use
and HIV/HCV screening. These conclusions will help us
understand the benefits of and modifications needed for
MAT +A-CHESS (and MAT alone) to sustain recovery
over the long term.
Discussion
This study is the first to our knowledge to test whether
MAT for OUDs, when combined with a smartphone-
based relapse prevention system, can significantly im-
prove long-term recovery from opioid dependence when
compared with MAT alone. The study will also explore
for whom, and under what circumstances, A-CHESS
does and does not work, and whether the tested bundle
of services can reduce relapse-related health service use.
We believe that the HIV/HCV component of the study
adds value to the intervention in two ways: (1) the
prevalence of HIV/HCV infection is high among opioid-
using populations, yet most addiction treatment centers
do not perform routine testing; bundling HIV/HCV ser-
vices with A-CHESS could improve screening rates in a
high-risk population for two serious but highly treatable
conditions, (2) screening for HIV/HCV is consistent
with the project’s overall goal of improving access to
comprehensive health services for opioid-dependent
patients, rather than focusing narrowly on promoting
abstinence from opioids. We recognize that, despite the
availability of evidence-based interventions, many
patients who have injected opioids will relapse. The bun-
dled intervention seeks to meet a public health goal of
reducing the number of people who are infected with
HIV or HCV but are unaware of being infected and,
therefore, continue to place others at risk.
Public health impact
mHealth systems can attend to patients nearly as con-
stantly as addiction does. At the end of this project, we
will understand whether bundling MAT with an
mHealth relapse prevention system can improve long-
term recovery from opioid dependence. Just as import-
ant, we will better understand factors that will improve
the design and delivery of treatment. This new know-
ledge could have wide and lasting benefits for patients
who suffer from SUDs and other chronic conditions and
for the health systems designed to help them.
Trial status
The trial has received ethical approval and recruited 23
participants to date (8 June 2016). We anticipate ending
recruitment in February 2018.
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